布地奈德+特布他林治疗急性加重期慢阻肺的临床效果和肺功能改善情况  

Clinical Effect of Budesonide+Terbutaline Treatment on Acute Exacerbation Chronic Obstructive Pulmonary Disease and the Improvement Situation of the Lung Function

作　　者：韦红梅[1] Wei Hongmei(Heibei Province Guo’an Hospital, Guo’an 071200, China)

机构地区：[1]河北省安国市医院,河北安国071200

出　　处：《黑龙江科学》2022年第6期128-129,共2页Heilongjiang Science

摘　　要：研究布地奈德+特布他林治疗急性加重期慢阻肺患者的临床效果和肺功能改善情况。选取96例急性加重期慢阻肺患者为研究对象,将其分为研究组与参照组,每组各48例。研究组采用布地奈德+特布他林治疗,参照组单用特布他林治疗,对比两组患者的临床效果及呼吸次数、氧合指数、浅快呼吸指数等呼吸功能改善情况。干预期结束后,研究组的临床疗效为93.75%,显著优于参照组的66.67%;研究组的呼吸次数、氧合指数、浅快呼吸指数等呼吸功能显著优于参照组,差异均有统计学意义(P<0.05)。对急性加重期慢阻肺患者实施布地奈德+特布他林治疗干预,可有效改善患者的临床效果及呼吸功能。The study explores the clinical effect of budesonide+terbutaline treatment on acute exacerbation chronic obstructive pulmonary disease and the improvement situation of the lung function.96 patients with acute exacerbation chronic obstructive pulmonary disease are selected as the research objects,and they are divided into research group and observation group,with 48 patients in each group.Research group receive budesonide+terbutaline treatment,and control group receive terbutaline treatment.Clinical effect and respiratory function improvement situation,such as respiratory rates,oxygenation index and rapid-shadowing-breathing index,of two groups are compared.After intervention,the clinical effect of research group is 93.75%,which is better than 66.67%in control group.Respiratory function,such as respiratory rates,oxygenation index and rapid-shadowing-breathing index,of research group is significantly better than control group,with statistically significant difference(P<0.05).Budesonide+terbutaline treatment on acute exacerbation chronic obstructive pulmonary disease can effectively improve patient’s clinical effect and respiratory function.

关 键 词：布地奈德 特布他林 急性加重期慢阻肺 临床效果 肺功能 

分 类 号：R452[医药卫生—治疗学]